DETECTION OF FAMILIAL DEFECTIVE APOLIPOPROTEIN B-100 AMONG PATIENTS CLINICALLY DIAGNOSED WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN MARITIME CANADA

被引:3
作者
MORASH, B
GUERNSEY, DL
TAN, MH
DEMPSEY, G
NASSAR, BA
机构
[1] DALHOUSIE UNIV,DEPT PHYSIOL & BIOPHYS,HALIFAX,NS,CANADA
[2] DALHOUSIE UNIV,DIV MOLEC PATHOL & MOLEC GENET,HALIFAX,NS,CANADA
[3] DALHOUSIE UNIV,DEPT MED,HALIFAX,NS,CANADA
[4] DALHOUSIE UNIV,DEPT BIOCHEM,HALIFAX,NS,CANADA
[5] DALHOUSIE UNIV,DEPT PATHOL,DIV CLIN CHEM,HALIFAX,NS,CANADA
关键词
FAMILIAL DEFECTIVE APOLIPOPROTEIN B-100 (FDB); APOLIPOPROTEIN B-100 (APO B-100); FAMILIAL HYPERCHOLESTEROLEMIA (FH); LOW-DENSITY LIPOPROTEIN (LDL) RECEPTOR; POLYMERASE CHAIN REACTION (PCR); RESTRICTION ISOTYPING;
D O I
10.1016/0009-9120(94)90028-0
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Familial defective apolipoprotein B-100 (FDB) is a genetic disorder resulting from a mutation in the apolipoprotein B-100 (apo B-100) gene, most frequently at position 3500, in which arginine is substituted for glutamine in the mature protein. This mutation drastically decreases the affinity of the mutant apo B-100 particle for the low-density lipoprotein (LDL) receptor, and hence decreases the clearance of cholesterol from the circulation. Familial hypercholesterolemia (FH), also a disorder of lipid metabolism, results from mutations in the gene for the LDL receptor. Both FDB and heterozygous FH occur at approximately the same frequency (1 in 500) among Caucasians and both produce clinical symptoms and signs that can be indistinguishable. Polymerase chain reaction (PCR) amplification and subsequent restriction analysis have been used to detect the substitution at codon 3500 in the apo B-100 gene using mutagenic PCR primers. At least one proband from 10 unrelated families with a history of hypercholesterolemia was screened by mutagenic PCR for FDB. Only one of 10 patients demonstrated the mutation for FDB. The mutant apo B-100 allele was shown to segregate with other clinically affected family members. These results demonstrate that molecular analysis is essential to distinguish between FDB and heterozygous FH in hypercholesterolemic families.
引用
收藏
页码:265 / 272
页数:8
相关论文
共 28 条
[1]  
BERSOT TP, 1993, J LIPID RES, V34, P1149
[2]   A RECEPTOR-MEDIATED PATHWAY FOR CHOLESTEROL HOMEOSTASIS [J].
BROWN, MS ;
GOLDSTEIN, JL .
SCIENCE, 1986, 232 (4746) :34-47
[3]   FAMILIAL DEFECTIVE APO-B-100, CHARACTERIZATION OF AN ITALIAN FAMILY [J].
CORSINI, A ;
MCCARTHY, BJ ;
GRANATA, A ;
SORIA, LF ;
FANTAPPIE, S ;
BERNINI ;
ROMANO, C ;
ROMANO, L ;
FUMAGALLI, R ;
CATAPANO, AL .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1991, 21 (04) :389-397
[4]  
FANTAPPIE S, 1992, J LIPID RES, V33, P1111
[5]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[6]  
GEISEL J, 1992, EUR J CLIN CHEM CLIN, V30, P729
[7]  
HANSEN PS, 1991, J LIPID RES, V32, P1229
[8]   ISOLATION OF PROBES DETECTING RESTRICTION FRAGMENT LENGTH POLYMORPHISMS FROM X-CHROMOSOME-SPECIFIC LIBRARIES - POTENTIAL USE FOR DIAGNOSIS OF DUCHENNE MUSCULAR-DYSTROPHY [J].
HOFKER, MH ;
WAPENAAR, MC ;
GOOR, N ;
BAKKER, E ;
VANOMMEN, GJB ;
PEARSON, PL .
HUMAN GENETICS, 1985, 70 (02) :148-156
[9]   MAPPING OF THE HUMAN APO-B GENE TO CHROMOSOME 2P AND DEMONSTRATION OF A 2-ALLELE RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISM [J].
HUANG, LS ;
MILLER, DA ;
BRUNS, GAP ;
BRESLOW, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (03) :644-648
[10]  
INNERARITY TL, 1990, J LIPID RES, V31, P1337